Prognostic Value of lncRNA PVT1 for Patients with Gastric Cancer: A Meta-Analysis

Objective. To evaluate the prognostic value of lncRNA PVT1 for patients with gastric cancer. Methods. A comprehensive literature searching was performed in PubMed, Cochrane Library, Web of Science, Embase, CNKI, CBM, and Wanfang Database to identify published studies on the expression level of lncRNA PVT1 in human gastric cancer. STATA 12.0 was conducted to perform the meta-analysis. Clinical outcomes including patients' age, genders, TNM stage, OS, and DFS were assessed in the study. Results. A total of 8 studies involving 747 patients were included in this meta-analysis. The results of meta-analysis showed that higher expression level of lncRNA PVT1 was associated with GC patients' gender (for male: OR=2.27, 95% CI: 1.67~3.07, P=0.000), invasion depth (for T3~4: OR=3.98, 95% CI: 2.85~5.56, P=0.000), poorer OS (HR=1.68, 95% CI: 1.43~1.97, P=0.000), and DFS (HR=1.74, 95% CI: 1.44~2.08, P=0.000). Conclusion. Higher expression level of lncRNA PVT1 is significantly associated with GC patients' gender, invasion depth, poorer OS, and worse DFS. lncRNA PVT1 might act as a novel predictive biomarker of poor prognosis and clinicopathological characteristics for gastric cancer.